The US Food & Drug Administration is likely to revise the plans for assessing the opioid class-wide risk management program to ask for a number of different studies to test aspects of the continuing medical education program incorporated into the Risk Evaluation & Mitigation Strategy program.
Based on feedback during a 11 December workshop on the opioid REMS assessment process, FDA may need to “to...




